Novo Nordisk A/S Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Investors With Losses To Reach OutAccesswire • 02/05/25
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts TodaySeeking Alpha • 02/05/25
Amid Novo Nordisk's Win for Ozempic's Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists' Rising Influence in GLP-1 RA UtilizationGlobeNewsWire • 02/05/25
Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026Benzinga • 02/05/25
Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positionedReuters • 02/05/25
Novo Nordisk reports strong Q4 profits but warns of slower growth in 2025Proactive Investors • 02/05/25
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024GlobeNewsWire • 02/05/25
Shareholders With Losses In Novo Nordisk A/S Have Opportunity To Lead The Schall Law Firm In A Securities Fraud CaseAccesswire • 02/05/25
Shareholder Rights Law Firm Robbins LLP Urges NVO Shareholders with Large Losses to Seek Counsel for the Novo Nordisk A/S Class ActionPRNewsWire • 02/05/25
NVO CLASS ACTION ALERT: Novo Nordisk Investors are Notified to Contact BFA Law before March 25 Deadline in Securities Fraud Class ActionAccesswire • 02/04/25
NVO CLASS ACTION ALERT: BFA Law Alerts Novo Nordisk Investors that the Company has been Sued for Fraud – Contact BFA Law by March 25 Class Action Deadline (NYSE:NVO)GlobeNewsWire • 02/04/25
Shareholders that lost money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreAccesswire • 02/04/25